Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in—the cell of origin—can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.
Robert Wechsler-Reya, Ph.D., professor and program director at Sanford-Burnham Medical Research Institute, and his team study medulloblastoma, the most common malignant brain cancer in children. A few years ago, they made an important discovery: medulloblastoma can originate from one of two cell types: 1) stem cells, which can make all the different cell types in the brain, or 2) neuronal progenitor cells, which can only make neurons.
Stem cells and progenitor cells are regulated by different growth factors. So, Wechsler-Reya thought, maybe the tumors arising from these cells respond differently to different therapies…
In a study published in the journal Oncogene, he and his team show that this is indeed the case. They looked at one growth factor in particular—basic fibroblast growth factor (bFGF)—and found that while it induces stem cell growth, it also inhibits neuronal progenitor cell growth.
What's more, the researchers discovered that bFGF also blocks the growth of tumors that originate from progenitors. When they administered bFGF into a mouse model of medulloblastoma, it dramatically inhibited tumor growth.
Although bFGF itself can't be used as a drug (it would cause too many off-target effects), this study suggests that molecules like it might be used to treat medulloblastoma—but only for tumors that have the appropriate origins.
"Medulloblastomas are not all alike, and the same is true for cancers of the breast, prostate and other tissues. It's critical for us to figure out how tumors differ from one another, so we can find ways to personalize cancer diagnosis and come up with treatments that are more effective and less harmful," Wechsler-Reya says.
Sanford-Burnham Medical Research Institute: http://www.burnham-inst.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
The complicated science behind picky eating is giving experts plenty of food for thought
The compound kills disease-causing parasites by popping them like water balloons
The U.S. had planned to build 17 treatment units across Liberia, one in each county's major town. Now that more cases are appearing in remote areas, the Army may need to rethink its strategy.
A woman is thought to be spreading Ebola in a remote village. So health workers spend four hours trekking through the bush to track her down. By the time they make it, it's too late.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?